NASDAQ: RANIRani Therapeutics Holdings Inc Stock
$5.40+0.93 (+20.81%)
Updated Apr 12, 2024
RANI Price
$5.40
Fair Value Price
-$0.93
Market Cap
$270.85M
52 Week Low
$1.82
52 Week High
$5.79
P/E
-4.06x
P/B
21.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$33.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.52
Operating Cash Flow
-$51M
Beta
0.84
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RANI Overview
Rani Therapeutics Holdings, Inc. is as a clinical stage biotherapeutics company developing orally administered biologics. Its product pipeline includes RT-101 for the treatment of neuroendocrine tumors and acromegaly, RT-105 to treat psoriatic arthritis, and RT-102 to treat osteoporosis. The company is also developing the RaniPill capsule, a platform intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani Therapeutics was incorporated in 2012 and is headquartered in San Jose, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RANI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RANI ($5.40) is overvalued by 680.27% relative to our estimate of its Fair Value price of -$0.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RANI ($5.40) is not significantly undervalued (680.27%) relative to our estimate of its Fair Value price of -$0.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RANI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RANI due diligence checks available for Premium users.
Be the first to know about important RANI news, forecast changes, insider trades & much more!
RANI News
Valuation
RANI fair value
Fair Value of RANI stock based on Discounted Cash Flow (DCF)
Price
$5.40
Fair Value
-$0.93
Undervalued by
680.27%
RANI ($5.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RANI ($5.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RANI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RANI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.06x
Industry
14.72x
Market
42.64x
RANI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
21.05x
Industry
5.93x
RANI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RANI's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.1M
Profit Margin
0%
RANI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$57.9M
Liabilities
$32.5M
Debt to equity
2.52
RANI's short-term assets ($50.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RANI's short-term assets ($50.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RANI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
$13.3M
Financing
$96.0k
RANI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RANI vs Biotech Stocks
Rani Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.